Avivagen Inc. (VIV:TSX.V; CHEXF:OTCMKTS) announced in a news release it received the first order from Malaysia for its OxC-beta™ Livestock following recent product approval in the country for broilers and swine.
The order, obtained through Avivagen's distribution partner in Malaysia, TLC Veterinary Services, is for 100 kilograms of the antibiotics-free feed additive.
"As is evident by our experience in the Philippines, we are confident that this initial order will lead to greater demand in Malaysia and expanded use of OxC-beta Livestock over time," Avivagen CEO Kym Anthony said in the release.
"The Malaysian government has stated its intention to move to antibiotic-free chicken production in 2020, representing a new opportunity for growth for Avivagen," the company noted.
In other news, Avivagen garnered a follow-up order for the same product from its distribution partner in Thailand.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
